Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $222.8 million.

  • Rocket Pharmaceuticals' Cash & Equivalents fell 547.31% to $222.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $222.8 million, marking a year-over-year decrease of 547.31%. This contributed to the annual value of $163.6 million for FY2024, which is 19270.71% up from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Cash & Equivalents stood at $222.8 million for Q3 2025, which was down 547.31% from $271.5 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Cash & Equivalents ranged from a high of $466.4 million in Q1 2021 and a low of $55.9 million during Q4 2023
  • Moreover, its 5-year median value for Cash & Equivalents was $307.0 million (2023), whereas its average is $297.0 million.
  • Per our database at Business Quant, Rocket Pharmaceuticals' Cash & Equivalents crashed by 6021.55% in 2023 and then surged by 19270.71% in 2024.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Cash & Equivalents stood at $232.7 million in 2021, then tumbled by 39.61% to $140.5 million in 2022, then crashed by 60.22% to $55.9 million in 2023, then soared by 192.71% to $163.6 million in 2024, then soared by 36.16% to $222.8 million in 2025.
  • Its Cash & Equivalents was $222.8 million in Q3 2025, compared to $271.5 million in Q2 2025 and $318.2 million in Q1 2025.